An Evidence-Based Preventive Checklist for Men: What the Guidelines Actually Support by Age

Only a handful of preventive screenings for men rest on strong evidence, and knowing which ones lets you spend a short appointment on what matters. The list with the firmest guideline support is short: blood pressure measurement, colorectal cancer screening starting at 45, lung cancer screening for eligible people with a smoking history, cholesterol-based decisions about statins, and a one-time aneurysm ultrasound for older men who smoked. Prostate cancer screening is a genuine judgment call the guidelines ask you to make with a clinician, not a box to check by default. This piece is educational and not medical advice; every item below is meant to inform a conversation, not replace one.

How to read a screening recommendation

The US Preventive Services Task Force (USPSTF) grades each service by how confident the evidence is that benefits outweigh harms. A grade of A or B means the net benefit is at least moderate and the service is generally recommended. A grade of C means the service should be offered selectively, based on individual circumstances rather than applied to everyone. A grade of D means the harms outweigh the benefits, and an I grade means the evidence is insufficient to judge. Screening is never free of downsides: false positives, follow-up procedures, and overdiagnosis are real, which is why the grade matters as much as the test name.

The screenings with the strongest support

Blood pressure. The USPSTF gives screening for high blood pressure in adults its strongest tier of recommendation. For men 40 and older, or those at increased risk, periodic measurement is reasonable; younger adults with prior normal readings and no added risk can be checked less often. The Task Force also advises confirming an elevated office reading with measurements taken outside the clinic before anyone starts treatment, which guards against overtreating a number inflated by the visit itself.

Colorectal cancer. Guidance shifted in 2021 to begin screening earlier. The USPSTF recommends screening for all adults aged 50 to 75 and extends that recommendation down to adults aged 45 to 49. Several options exist, from stool-based tests to colonoscopy, and the right one depends on preference and access rather than a single mandated method. Between 76 and 85 the recommendation softens to a selective one: screen based on overall health and prior screening history rather than age alone.

Lung cancer. The 2021 USPSTF recommendation (grade B) covers annual low-dose CT for adults aged 50 to 80 who have a 20 pack-year smoking history and either currently smoke or quit within the past 15 years. That 2021 update widened eligibility from the earlier 55-to-80, 30-pack-year threshold, bringing in more people at meaningful risk. Screening is meant to stop once someone has been smoke-free for 15 years or develops a condition that would limit either life expectancy or the ability to tolerate treatment.

Cholesterol and statin decisions. Rather than a single cholesterol target, the 2022 USPSTF guidance frames statins for primary prevention around estimated cardiovascular risk. For adults aged 40 to 75 with at least one risk factor (such as high cholesterol, diabetes, high blood pressure, or smoking) and an estimated 10-year cardiovascular risk of 10 percent or higher, the Task Force recommends a statin (grade B). When that estimated risk falls between 7.5 and 10 percent, the recommendation is to offer a statin selectively (grade C), because the expected benefit is smaller. For adults 76 and older without prior cardiovascular disease, the evidence was judged insufficient (grade I).

Abdominal aortic aneurysm. The USPSTF recommends a one-time ultrasound for men aged 65 to 75 who have ever smoked. For men in that age band who never smoked, the recommendation is to offer the scan selectively rather than routinely. This is one of the few screenings with a clear age-and-history trigger, which makes it easy to raise at the right visit.

Prostate cancer: a decision, not a default

Prostate screening is where the framing matters most. The USPSTF gives PSA-based screening for men aged 55 to 69 a grade C, meaning the decision to screen should be an individual one made after discussing benefits and harms with a clinician. The Task Force describes a small potential mortality benefit alongside real harms: false positives, biopsies, overdiagnosis of cancers that would never have caused trouble, and treatment side effects such as incontinence and erectile dysfunction. For men 70 and older, the recommendation is grade D, against routine PSA-based screening, because the expected harms outweigh the benefits in that group. The point is not that screening is wrong, but that a reasonable, well-informed man could choose either way, which is exactly what a grade C recommendation signals.

Where hormones do not belong on the checklist

Low testosterone testing is sometimes marketed as preventive maintenance, so it is worth separating what changed from what it means. In February 2025 the FDA issued class-wide labeling changes for testosterone products, removing the boxed warning language about increased cardiovascular risk after the TRAVERSE trial found no increase in major adverse cardiovascular events among men treated for hypogonadism. At the same time, the FDA added a warning about increased blood pressure across the class and retained a limitation-of-use statement noting these products are not established for age-related, as opposed to medically diagnosed, low testosterone. A label change describes what a product's documentation now legally says; it is not an endorsement, a recommendation to start therapy, or a safety all-clear, and testosterone is a treatment for a diagnosed condition rather than a screening item. Whether to test or treat is an individual decision made with a clinician who can weigh the diagnosis, the blood pressure signal, and the specific trial population.

Putting it together

A grounded checklist is less about volume than about matching each test to your age, history, and the strength of the evidence behind it. Blood pressure, colorectal screening from 45, lung screening if you qualify, a statin conversation anchored to your calculated risk, and an aneurysm scan for older men who smoked are the items with the firmest backing. Prostate screening deserves a real conversation, not a reflex. Bringing this framing to a visit turns a rushed appointment into a set of shared decisions you actually understand.